Real-world evidence shows different herpes zoster risks for asthma biologics, indicating important safety considerations.
Summary Real‐world evidence on herpes zoster risk across asthma biologics is limited. While most agents demonstrated comparable risks, omalizumab showed a higher risk than benralizumab and dupilumab.
No takes yet. Share an insight, caveat, or question.
Hung et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: